Area of research
Oncology · Reproductive Medicine
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, and Chemokine receptors and signaling.
TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7).
Large language models-enabled digital twins for precision medicine in rare gynecological tumors
The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study
PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer
PARP-Inhibitor (PARPi-) Reinduktion beim rezidivierenden Ovarialkarzinom: eine prospektive, multizentrische Studie zur Versorgungsrealität in Bayern, dem klinischen Outcome sowie der translationalen Biomarkerforschung (BZKF-OVAR 1-Studie)
Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer.
PubMed 2023cited by 7position: middle
Data from The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ‐secretase activity
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Die Überexpression von CX3CL1 führt zu vermehrtem Tumorwachstum aber auch erhöhtem Ansprechen auf eine Behandlung mit Trastuzumab in Humanisierten Tumormäusen
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Das Chemokin CX3CL1 erhöht die Immuninfiltration, reduziert Tumorwachstum und -metastasierung und verbessert die Trastuzumab-Therapie in vitro und in vivo
MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases
Development of endothelium-denuded human umbilical veins as living scaffolds for tissue-engineered small-calibre vascular grafts
Neue Verwendungsmöglichkeiten von Nachgeburtsgewebe für die Regenerative Medizin